Skip to main content
NBTX
NASDAQ Life Sciences

Nanobiotix Launches $87M Global Follow-On Offering to Fund R&D

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
8
Price
$40.92
Mkt Cap
$2.077B
52W Low
$3.64
52W High
$57.14
Market data snapshot near publication time

summarizeSummary

Nanobiotix has launched a global follow-on offering to raise approximately $87 million through ADSs, ordinary shares, and pre-funded warrants, with proceeds primarily funding R&D and general corporate purposes.


check_boxKey Events

  • Global Follow-On Offering Launched

    Nanobiotix has launched a global follow-on offering to raise approximately €75 million (around $87 million) through a public offering of American Depositary Shares (ADSs) in the U.S. and an offering of ordinary shares and pre-funded warrants (PFWs) in Europe.

  • Proceeds Allocated to R&D and Operations

    The net proceeds will be used primarily for research and development, with less than 10% supporting JNJ-1900 (NBTXR3) development, 50-60% advancing Nanoprimer and other platforms, and 30-40% for general corporate purposes.

  • Pricing Determined by Book-Building

    The final offering price will be determined through a book-building process, with ordinary shares priced at least equal to the volume-weighted average price (VWAP) over the last three trading sessions, subject to a maximum 15% discount.

  • Insider and Company Lock-Up

    Executive board members, supervisory board members, and the company itself are subject to a 90-day contractual lock-up period following the pricing of the Global Offering, subject to customary exceptions.


auto_awesomeAnalysis

Nanobiotix has launched a significant global follow-on offering aiming to raise approximately €75 million (around $87 million). This capital raise, representing over 4% of the company's market capitalization, is crucial for a late-clinical stage biotechnology company like Nanobiotix, providing essential funding for the development and advancement of its JNJ-1900 (NBTXR3) program and other Nanoprimer platforms. While dilutive for existing shareholders, securing this capital extends the company's operational runway and supports its strategic development initiatives. The offering follows a preliminary announcement and indicates the company is actively moving forward with securing its financial future amidst a period of high corporate activity.

At the time of this filing, NBTX was trading at $40.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed NBTX - Latest Insights

NBTX
May 21, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
NBTX
May 21, 2026, 2:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
NBTX
May 20, 2026, 6:30 PM EDT
Filing Type: 6-K
Importance Score:
8
NBTX
May 20, 2026, 4:51 PM EDT
Filing Type: 6-K
Importance Score:
9
NBTX
May 20, 2026, 4:06 PM EDT
Filing Type: 424B5
Importance Score:
7
NBTX
May 17, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
NBTX
May 04, 2026, 5:45 PM EDT
Filing Type: 6-K
Importance Score:
8
NBTX
Apr 20, 2026, 2:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
NBTX
Mar 31, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
9
NBTX
Mar 31, 2026, 4:27 PM EDT
Filing Type: 20-F
Importance Score:
9